Back
About
Caris Life Sciences is a leading, patient-centric, next-generation AI TechBio company and a pioneer in precision medicine. The company develops and commercializes innovative solutions aimed at transforming healthcare through the integration of comprehensive molecular data and scalable artificial intelligence (AI) and machine learning (ML) technologies. Its entire portfolio of precision medicine offerings is designed to benefit patients—initially with a focus on oncology—and serves clinical, academic, and biopharmaceutical markets.
Founded in 2008, Caris was established on the vision that combining a vast, consistently generated body of molecular information with robust data-driven insights could unlock the full potential of precision medicine. Over the past 17 years, the company has developed a comprehensive suite of proprietary molecular profiling solutions and built what it believes to be one of the most extensive multi-modal clinico-genomic datasets in oncology. This dataset is based on more than 6.5 million tests conducted across over 849,000 cases, generating over 38 billion molecular marker measurements.
Caris’ platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), AI/ML technologies, and high-performance computing. The strength of this differentiated platform has enabled the development of advanced diagnostic solutions that span the full continuum of cancer care—including early detection, minimal residual disease (MRD) tracking, therapy selection, and treatment monitoring. Additionally, the platform supports the creation of molecular signatures and the discovery and development of novel precision medicine therapeutics.
The company’s current commercial portfolio is focused on oncology and includes MI Profile, its tissue-based molecular profiling solution that has been the primary revenue driver, and Caris Assure, a novel, universal blood-based molecular profiling solution broadly launched in the first quarter of 2024 for therapy selection.
Headquarters
750 W. John Carpenter Freeway Suite 800 Irving, TX 75039
Team
David Dean Halbert - Chairman, Founder and CEO
Financial information
Underwriters
BofA Securities, J.P. Morgan, Goldman Sachs, Citigroup, TD Cowen, Evercore ISI, Guggenheim Securities
Calls within Tajikistan are free
Investments
Information
The information provided is for informational purposes only and should not be considered as an offer to buy or sell foreign currency, securities and/or other financial instruments. The information presented on this website is not an individual investment recommendation. Financial instruments or transactions mentioned in this section may not be suitable for you, may not correspond to your investment profile, financial situation, investment experience, knowledge, investment objectives, attitude to risk and profitability.
LLC "Exchange Broker" does not guarantee and does not promise future profitability of investments, does not guarantee the reliability of possible investments and the stability of possible income. Investment results in the past do not guarantee income in the future.
LLC "Exchange Broker" is not responsible for possible investor losses in the event of transactions and investments in financial instruments, and also does not guarantee the return, effectiveness and profitability of investments.
LLC "Exchange Broker" hereby informs that it operates in the securities market in accordance with the following professional participant licenses issued by the Ministry of Finance of the Republic of Tajikistan: depository activity No.010/25 dated 25.06.2025; brokerage activity No.007/25 dated 25.06.2025; dealer activity No.008/25 dated 25.06.2025 and securities management activity No.009/25 dated 25.06.2025, and also informs about the risk of a conflict of interest, including as a result of combining various types of professional activity in the securities market.